The large-scale production of plant-derived secondary metabolites (PDSM) in bioreactors to meet the increasing demand for bioactive compounds for the treatment and prevention of degenerative diseases is nowadays considered an engineering challenge. Plant cell culture (PCC) is nowadays recognized as a promising, renewable, sustainable, and environmentally friendly alternative to obtain PDSM out of wild plants. PCC accounts for the virtues of whole-plant cultivation systems and offers significant advantages, such as controlled manufacture due to standardized environmental conditions, i.e., it is not seasonal dependent, makes use of low amounts of water, and pesticides and herbicides are not required, achieving better quality in the desired product.
Compound | Plant Species | Biological Activity/ Pharmaceutical Use |
Extraction Yield | Type of Culture | Ref. | |
---|---|---|---|---|---|---|
Mother Plant | In Vitro Cell Culture | |||||
Shikonin | Lithospermum erythrorhizon Alkanna tinctoria Tausch |
Anticancer, antibacterial, anti-inflammatory, hepatic steatosis attenuator, antitumor, and antioxidants | 10−20 mg/g | 150−200 mg/g | CSC | [58,59,60,61,62] |
Echium plantagineum L. | 36.25 mg/L | HRC | [63] | |||
Anthraquinones | Morinda citrifolia Rubia cordifolia Senna obtusifolia |
Antimicrobial, antifungal, hypotensive, analgesic, antimalarial, gastroprotective, antioxidant, hepatoprotective and antileukemic, and mutagenic functions | 3 mg/g | 100–200 mg/g | HRC CCC CSC |
[64,65,66,67] |
Rosmarinic acid | Ocimum basilicum | Antioxidant, anti-inflammatory, antiviral activities | 8.78–9.4 mg/g | 12.32–21.28 mg/g | CSC | [68,69] |
Origanum vulgare | 23.53 mg/g | 31.25 mg/g | CSC | [70,71] | ||
Satureja khuzistanica | 12 mg/g | 38 mg/g | CSC | [72,73] | ||
Coleus blumei | 30 mg/g | 270 mg/g | CSC | [32] | ||
Salvia officinalis | 30 mg/g | 360 mg/g | CSC | |||
Berberine | Thalictrum minus | Effects antitumor, anticancer, lower blood lipid, lower blood glucose, anti-osteoporosis, anti-osteoarthritis, antibiotic, and anti-inflammatory | 0.1 mg/g | 0.8 mg/mL | CSC | [74,75,76,77,78,79] |
Coptis japonica | 20–40 mg/g | 132 mg/g | CSC | |||
Coscinium fenestratum | 1 mg/g | 178 mg/g | CCC | |||
Ginsenosides | Panax ginseng | Antitumor, immunological, anti-inflammation, anticancer, antidiabetic, and cardiovascular-protective | 0.015–8 mg/g | 36.4–80 mg/g | HRC | [57,80,81] |
3.4–28.9 mg/g | CSC | |||||
15.1–105.6 mg/g | ARC | |||||
Panax japonicus | 20–50 mg/g | CSC | ||||
Panax notoginseng | 60 mg/g | CCC | ||||
71.94 mg/g | ARC | |||||
40 mg/g | CSC | |||||
Diosgenin | Dioscorea deltoidea | Anticancer, antidiabetic, anticoagulant, antithrombosis, anti-inflammatory, antiviral, anti-ageing | 0.4−3 mg/g | 72 mg/g | CSC | [82] |
3.5–16 mg/g | CCC | |||||
Dioscorea bulbifera | 12 mg/g | CCC | ||||
Helicteres isora L. | 1–5 mg/g | 8.64 mg/L | CSC | [83] | ||
23 mg/g | CCC | [84] | ||||
Ajmalicine | Catharanthus roseus | Antihypertensive, obstructive circulatory diseases treatment | 3 mg/g | 63 mg/L | CCC | [85] |
10 mg/g | CSC | [86,87] | ||||
34 mg/L | HRC | |||||
Paclitaxel | Taxus chinensis | Anticancer | 0.02 mg/g | 1.5 mg/g | CSC | [88] |
Podophyllotoxin | Linum narbonense | Vigorous antimitotic and antiviral activities and anticancer | 0.5 mg/g | 1.57 mg/g | CCC | [89] |
Juniperus chinensi | 0.025 mg/g | 189.91 mg/g | CSC | |||
Linum flavum | 1.6 mg/g | 2 mg/g | CSC | |||
Artemisinin | Artemisia annua L. | Treat multi-drug-resistant strains of falciparum malaria | 1–15 mg/g | 9.33–110.2 mg/L | CSC | [90,91] |
Phenolic Acids | Verbena officinalis | Antimicrobial, secretolytic, expectorant, and diuretic agent | 136.59 mg/g | 126.55 mg/g | CCC | [92] |
(rosmarinic, chlorogenic, and ferulic acid) | 189.91 mg/g | CSC | ||||
Resveratrol | Vitis vinifera L. | Reduced coronary heart disease mortality rates and atherosclerosis, inhibiting low-density lipoprotein oxidation, and carcinogenesis | NR | 277.89 µg/g | CSC | [7] |
Product | Species | Pharmaceutical Use | Manufacturer, Tradename, and Scale of Production |
Type of Culture | Reference |
---|---|---|---|---|---|
Rosmarinic acid | Coleus blumei | Anti-inflammatory | ANattermann & Cie. Gmbh, www.sanofi.de (accessed on 30 October 2021) |
CSC | [103] |
Echinacea polysaccharides | Echinacea purpurea | Immunostimulant, anti-inflammatory | Diversa, 75,000 L bioreactor | CSC | [100,104] |
Berberines | Thalictrum minun | Anticancer; antibiotic; anti-inflammatory | Mitsui Chemicals, Inc., (75,000 Lbr) | CSC | [105] |
Coptis japonica | https://www.mitsuichemicals.com/ (accessed on 30 October 2021) | CSC | |||
Podophyllotoxin | Podophyllum spp. | Anticancer | Nippon Oil Company, Ltd. | CSC | [106] |
https://www.freepatentsonline.com/5336605.html (accessed on 30 October 2021) | OC | [107] | |||
Docetaxel | Taxus baccata | Ovarian cancer treatment | Phyton Biotech, Inc., Taxotere (150 kg/year) | CSC | [108,109] |
https://phytonbiotech.com/ (accessed on 30 October 2021) | |||||
Paclitaxel | Taxus spp. | Anticancer: FDA approved for the treatment of ovarian, breast, and lung cancers | Phyton Biotech, Inc., Taxol ® (1000 kg/year) | CSC | [110] |
https://phytonbiotech.com/ (accessed on 30 October 2021) | |||||
Samyang Genex Corporation., Genexol (32,000 Lbr) https://samyangbiopharm.com/eng/ProductIntroduce/injection01 (accessed on 30 October 2021) | CSC | [111] | |||
[112] | |||||
Scopolamine | Duboisia spp. | Anticholinergic; antimuscarinic; motion sickness, nausea, and intestinal cramping | Sumitomo Chemical Co., Ltd., Tokyo, Japan (50–20,000 Lbr) https://www.sumitomo-chem.co.jp/pharma-chem/ (accessed on 30 October 2021) |
HRC | [113,114] |
Shikonin | Lithospermum erythrorhizon | Anti-HIV, antitumor, anti-inflammatory | Xi’an NEO Biotech, Shikonin 95% | CSC | [100] |
http://www.extractneo.com/about (accessed on 30 October 2021) |
Bioreactor Configuration | Schematic Diagram * | Description | Advantages | Disadvantages | Ref. |
---|---|---|---|---|---|
Bubble column (BC) |
It is classified in the pneumatic-type bioreactor. They are constructed in cylindric columns where gas injection represents the only energy entrance to the system. BC bioreactors operate under constant bubbling where gas flows from the bottom to the top through nozzles, perforated plates, or spray rings, allowing not only the aeration process, but also helping the mixing and circulation of the fluid, without the need to install mechanical accessories. | Simple structure as no mechanical force is required to shake. Easier maintenance and reduces the risk of contamination due to the lack of mobile parts. Reduced effect of the shear stress. |
High foam formation under high gas flow rates. Poor oxygen transfer capabilities. Poor fluid mixing in highly viscous fluids. High levels of foaming under high-aeration conditions |
[24,94,116] | |
Airlift (ALB) | It is classified in the pneumatic-type bioreactor. This configuration is considered reasonably like STR, excepting for the impeller. They are tower reactors where fluid broth is mixed with a gas stream, which is compressed and injected at the bottom of the discharge pipe. The gas–fluid mix allows the creation ofdifferences in density and upward displacement. It is more suitable for hairy root and somatic embryo cultures. | Easy maintenance and reduces the risk of contamination due to the absence of mobile parts. Reduced effect of the shear stress. Higher oxygen transfer than that in BC. The energy required is provided by the compressed gas. |
High levels of foam formation under high gas flow rates. Poor fluid mixing in highly viscous fluids. Relatively poor oxygen transfer capabilities. |
[24,117,118,119] | |
Stirred tank bioreactor (STB) | It is grouped in the mechanically agitated bioreactor. This bioreactor consists in a mixer (turbine or propeller) installed within the tank reactor and may be equipped with gassing inlet stream. It can operate in batch, semi-continuous, or continuous mode [117,120]. | Efficient fluid mixing systems. High oxygen mass transfer capability. Convenient for high-viscous fluids. Comply with Good Manufacturing Practices. Easy scale-up. Highly adaptable to production scale and products. Impeller alternative. |
High energy cost owing to mechanical agitation. Contamination risk with mechanical seal. Some cells and metabolites are susceptible to shearing generated by the impeller and bursting gas bubbles. Depending on the operation mode, this configuration can represent high costs of maintenance, cleaning, and startup. |
[94,117,120,121] |
Species | Compounds | Operation Variables Evaluated | Biomass Production |
PDSM Production |
Ref. | ||
---|---|---|---|---|---|---|---|
In Shake Flask | In Bioreactor |
In Shake Flask | In Bioreactor | ||||
Scrophularia striata | Phenylethanoid glycosides | 50 mL SCC in 100 mL flask 110 rpm 25 °C |
5.0 L SCC in STR 10 L Fg: 0.5–1.0 L/min 110−170 rpm 25 ± 1 °C Darkness |
14.16 g/L | 15.64 g/L | The acteoside content in CSC in the bioreactor was about threefold higher than that in the shake flask | [122] |
Buddleja cordata | Verbascoside, linarin and hydroxycinnamic acids |
50 mL SCC in 250 mL flasks 110 rpm 26 ± 2 °C |
STR 2 L Fg: 1 vvm (ring diffuser Rushton impeller 400 rpm 26 ± 2 °C 16/8 h light to dark photoperiod |
11.8 g/L | 13.62 g/L | The content of phenolics was twofold higher in STR. | [123,124] |
Rubia tinctorum |
Anthraquinone | 25 mL SCC in 250 mL flasks 100 rpm 25 ± 2 °C 16/8 h photoperiod (140 µmol m−2 s−1) |
1.0 L SCC in STR 2 L Fg: 1 vvm Turbine impeller 450 rpm 25 ± 2 °C 16/8 h photoperiod (140 µmol m−2 s−1) |
330 g/L | 220 g/L | Anthroquinone production was 2.5 times higher in STR | [125] |
Arnebia sp. | Shikonin | 25 mL CSC in 250 mL flasks | Air-lift bioreactor | 1249.2 g/L | 480 g/L | The shikonin content was 2.6 times higher in the bioreactor than in the flask. Production remained without significant differences in both bioreactors | [126] |
100 rpm | 2 L working volume | ||||||
25 ± 2 °C | 25 ± 2 °C | ||||||
Continuous light | Fg: 2 L/min (sparger ring) | ||||||
(70 µmol/m2 s 1) | |||||||
STR 2 L | 1249.2 g/L | 450 g/L | |||||
Six-blade turbine impeller 100 rpm | |||||||
Fg: 2 L/min | |||||||
25 ± 2 °C | |||||||
Ocinum basilicum | Rosmarinic acid | 100 rpm | 7 L CSC in STR 10 L | Biomass was 8.4 times higher in bioreactor than in flask | Production increased 1.66 times in bioreactor | [69] | |
25 ± 2 °C | Marine impeller 100 rpm | ||||||
Fg: 25 L/min | |||||||
Satureja khuzistanica | Rosmarinic acid | 200 mL CSC in 1 L flask | 1 L CSC in culture bags 2 L | 13.6 g/L | 18.7 g/L | Production increased 2.5 times in bioreactor | [127] |
110 rpm | Batch mode | ||||||
25 °C | 20–30 rpm | ||||||
25 °C | |||||||
Fg: 0.1 vvm | |||||||
Darkness | |||||||
Vitis labrusca L. | Resveratrol | 100 mL CSC in 300 mL flasks | STR 5 L | NR | ≈35 g DW | Production increased 1.15 times in bioreactor | [128] |
110 rpm | Marine impeller 110 rpm | ||||||
23 °C | Fg: 0.15 vvm | ||||||
Darkness | |||||||
Santalum album L. | Squalene | 100 mL CSC in 250 L flask | Airlift bioreactor 7 L | 1.05 mg/g | 1.25 mg/g | Production increased 1.71 times in bioreactor in four weeks of culture | [129] |
90 rpm | Batch mode | ||||||
28 °C | 70–80 rpm | ||||||
Fg: 4 L/min | |||||||
28 ± 2 ° C |
Mathematical Equation | Conventional Name |
---|---|
rx=µ=µmax[Si][Si]+Kmrs=Yxsµ | Monod kinetics |
rx=µ=µmax[Si]([Si]2/Ki)+[Si]+Kmrs=Yxsµ | Expanded Monod kinetics |
rx=µ=µmax[Si][Si]+Km(1−[P][P]max)rs=Yxsµ | Expanded Monod kinetics |
rx=µ=µmax(1−exp(−[Si]/Km))rs=Yxsµ | Monod’s teacher Tessier kinetics. |
rx=µ=µmax[Si][Si]+KSXrs=Yxsµ | Contois kinetics. |
rx=µ=µmax(1−XKS)rs=Yxsµ | Logistic kinetics. |
dθxdt=−kin(θx−θss)mr=rs=θxk[Si][Si]+Km | Cell deactivation kinetics |
This entry is adapted from the peer-reviewed paper 10.3390/plants10122762